NBP

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: NERV ALXO BCYC CGEN FATE FHTX CDXS IKT NVCT AKTX

| Held by: IBB SPEM SBIO QQQS EWX GXC IBBQ BIB

Scroll to Statements

Index	-
Market Cap	219.22M
Enterprise Value	11.45M
Income	-46.43M
Sales	0.00M
Book/sh	2.00
Cash/sh	1.83
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	30
IPO	Jan 17, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.95
P/C	1.04
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.09
Current Ratio	8.09
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-0.44
EPS next Y	-0.73
EPS next Q	-0.12
EPS this Y	-130.95%
EPS next Y	-50.52%
EPS next 5Y	-
EPS past 3/5Y	52.47% -
Sales past 3/5Y	- -
EPS Y/Y TTM	37.91%
Sales Y/Y TTM	-
EPS Q/Q	-112.22%
Sales Q/Q	-100.00%
Earnings	May 14
EPS/Sales Surpr.	0.00% -

Insider Own	16.33%
Insider Trans	1.03%
Inst Own	22.86%
Inst Trans	-4.52%
ROA	-
ROE	-
ROIC	-19.92%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	9.29%
SMA50	2.37%
SMA200	-41.47%
Trades

Shs Outstand	115.38M
Shs Float	96.54M
Short Float	3.59%
Short Ratio	3.93
Short Interest	3.47M
52W High	6.79 -72.02%
52W Low	1.46 30.14%
Volatility	9.58% 9.01%
ATR (14)	0.16
RSI (14)	53.86
Beta	1.46
Rel Volume	0.55
Avg Volume	881.86K
Volume	482,331

Perf Week	-11.21%
Perf Month	19.50%
Perf Quarter	-21.81%
Perf Half Y	-52.50%
Perf YTD	-52.26%
Perf Year	-7.32%
Perf 3Y	-31.16%
Perf 5Y	-97.65%
Perf 10Y	-
Recom	1.00
Target Price	8.00
Prev Close	1.86
Price	1.90
Change	2.15%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-26	Resumed	H.C. Wainwright	Buy	$7 → $9
Oct-03-25	Initiated	Leerink Partners	Outperform	$9
Sep-09-25	Initiated	BTIG Research	Buy	$7
Dec-09-21	Initiated	Siebert Williams Shank	Buy	$96
Jun-02-21	Initiated	Daiwa Securities	Buy
Mar-15-21	Initiated	Needham	Buy	$75
Mar-03-21	Reiterated	H.C. Wainwright	Buy	$55 → $75
Feb-25-21	Initiated	Piper Sandler	Overweight	$75
Dec-07-20	Initiated	H.C. Wainwright	Buy	$55
Jul-27-20	Initiated	Cantor Fitzgerald	Overweight	$50
Feb-12-20	Initiated	China Renaissance	Buy
Feb-11-20	Initiated	Jefferies	Buy	$16

Show Previous Ratings

Jun-29-26 07:00AM	NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer (GlobeNewswire) +20.73%
Jun-16-26 07:00AM	NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer (GlobeNewswire)
May-28-26 07:00AM	NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 07:00AM	NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference (GlobeNewswire)
Apr-22-26 07:00AM	NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value (GlobeNewswire)
04:50PM	Loading…
Apr-07-26 04:50PM	NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-16-26 07:00AM	NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer (GlobeNewswire)
Mar-09-26 10:24AM	Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease (Benzinga)
07:00AM	NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study (GlobeNewswire)
Mar-03-26 09:05AM	NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 (GlobeNewswire) -7.25%
Mar-02-26 07:00AM	NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire) +5.18%
Feb-19-26 07:00AM	NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform (GlobeNewswire)
Feb-17-26 04:05PM	NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer (GlobeNewswire)
Feb-06-26 09:41AM	Amazon downgraded, Roblox upgraded: Wall Street's top analyst calls (The Fly) +11.11%
Jan-20-26 07:00AM	NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei (GlobeNewswire) +5.09%
08:00AM	Loading…
Jan-16-26 08:00AM	Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape (PR Newswire)
Jan-06-26 07:00AM	NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer (GlobeNewswire) -11.21%
Dec-30-25 07:00AM	NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026 (GlobeNewswire)
Dec-10-25 04:30PM	NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO (GlobeNewswire)
Dec-03-25 07:30PM	NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO (GlobeNewswire)
Nov-20-25 08:00PM	NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward (GlobeNewswire) -7.51%
Oct-22-25 12:35PM	I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 (GlobeNewswire) -6.04%
Oct-16-25 04:05PM	I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences (GlobeNewswire) +7.01% -12.04%
Oct-15-25 08:45AM	Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge (PR Newswire)
Oct-14-25 07:00AM	I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference (GlobeNewswire)
Oct-10-25 12:00PM	I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know (Zacks)
Oct-07-25 08:00AM	Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms (PR Newswire)
Oct-06-25 12:00PM	What Makes IMab (IMAB) a New Buy Stock (Zacks)
Sep-23-25 07:12PM	I-Mab (IMAB) Shows 83% Response Rate for Givastomig in Metastatic Gastric Cancer (Insider Monkey) -7.77%
Sep-08-25 08:30AM	I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments (GlobeNewswire)
12:00PM	Loading…
Aug-28-25 12:00PM	Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice (Zacks) -5.56%
Aug-25-25 07:00AM	I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee (GlobeNewswire) -5.30%
Aug-21-25 07:00AM	I-Mab to Participate in September Investor Conferences (GlobeNewswire)
Aug-20-25 07:00AM	I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +7.36%
Aug-11-25 07:00AM	I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers (GlobeNewswire) +14.08%
Aug-01-25 09:02AM	Everest Medicines Expands Strategic Investment in I-MAB (PR Newswire) +30.35%
08:00AM	I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares (GlobeNewswire)
Jul-17-25 07:00AM	I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health (GlobeNewswire)
Jul-14-25 07:00AM	I-Mab to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-09-25 07:20AM	I-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025 (Insider Monkey)
Jul-02-25 11:15AM	I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 (GlobeNewswire)
Jun-30-25 04:01PM	I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research (GlobeNewswire) -5.84%
Jun-26-25 06:30AM	I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 (GlobeNewswire) -27.34%
Jun-18-25 07:00AM	I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025 (GlobeNewswire) -5.67%
Jun-12-25 07:00AM	I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jun-11-25 09:55AM	I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross (Zacks) -5.68%
Jun-06-25 12:00PM	I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy? (Zacks) +6.99%
Jun-03-25 07:00AM	I-Mab to Participate in the H.C. Wainwright "HCW@Home" Series (GlobeNewswire) +46.09%
May-20-25 07:00AM	I-Mab to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 07:00AM	I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-30-25 07:00AM	I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025 (GlobeNewswire) +15.76%
Apr-14-25 09:35AM	After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) (Zacks) +42.81%
Apr-11-25 09:35AM	After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) (Zacks)
Apr-03-25 04:01PM	I-Mab Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.19% -6.86%
Mar-26-25 07:00AM	I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-25 04:30PM	I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
Mar-07-25 07:00AM	I-Mab Announces Accelerated Givastomig Phase 1b Study Progress (GlobeNewswire)
Feb-18-25 07:00AM	I-Mab to Participate in Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-04-25 07:30AM	I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-08-25 07:00AM	I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member (PR Newswire) +11.97%
Jan-07-25 05:38AM	I-Mab pauses CD73 antibody development in pipeline reshuffle (Clinical Trials Arena) -9.04%
Jan-06-25 07:00AM	I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program (PR Newswire) +14.91%
Nov-21-24 07:00AM	I-Mab to Participate at the Piper Sandler Healthcare Conference (PR Newswire)
Nov-14-24 07:00AM	I-Mab Reports Third Quarter 2024 Results (PR Newswire)
Nov-06-24 07:00AM	I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer (PR Newswire)
Oct-31-24 07:00AM	I-Mab to Release Q3 2024 Financial Results on November 14, 2024 (PR Newswire)
Oct-30-24 07:00AM	I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024 (PR Newswire) -5.93%
Oct-28-24 07:00AM	I-Mab to Participate at the Truist Securities BioPharma Symposium (PR Newswire)
Oct-25-24 07:28AM	I-Mab Biopharmas Strategic US Transition and Pipeline Focus (TipRanks)
Oct-09-24 12:00PM	IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Sep-16-24 04:01PM	I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 (PR Newswire)
Sep-10-24 07:00AM	I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer (PR Newswire)
Aug-28-24 07:00AM	I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates (PR Newswire) -7.14%
Aug-26-24 07:00AM	I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +7.00%
Aug-14-24 07:00AM	I-Mab to Release 1H 2024 Financial Results on August 28, 2024 (PR Newswire)
Aug-07-24 07:00AM	I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC) (PR Newswire)
Jul-15-24 07:30AM	I-Mab Announces Leadership Transitions (PR Newswire) -5.23%
Jun-06-24 07:00AM	I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer (PR Newswire)
04:45AM	I-Mab and BMS assess givastomig for gastric and oesophageal cancer (Pharmaceutical Technology)
Jun-05-24 07:00AM	I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers (PR Newswire)
May-23-24 05:05PM	I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 (GlobeNewswire)
May-22-24 07:00AM	I-Mab to Participate at the Jefferies Global Healthcare Conference (PR Newswire)
May-02-24 12:00AM	Q1 2024 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-30-24 07:00AM	I-MAB Filed 2023 Annual Report on Form 20-F (PR Newswire)
Apr-05-24 07:00AM	I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Apr-02-24 04:01PM	I-Mab Announces Closing of the Divestiture of Business Operations in China (PR Newswire)
Mar-14-24 05:00PM	I-Mab Reports Full Year 2023 Financial Results and Business Update (PR Newswire)
Mar-07-24 10:03AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-21-24 01:56AM	Q4 2023 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-07-24 08:28AM	I-Mab sheds China footprint to complete transformation into US-based biotech (FierceBiotech.com)
06:29AM	UPDATE 2-Biotech firm I-Mab to divest China operations, shift focus to US (Reuters)
06:00AM	I-Mab Signs Agreement to Divest its Assets and Business Operations in China (PR Newswire)
Nov-06-23 08:00AM	I-Mab Announces Participation at Jefferies and Piper Conferences in November (PR Newswire)
Nov-02-23 08:00AM	Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) (PR Newswire) +9.15%
Nov-01-23 08:00AM	I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 (PR Newswire) +6.99%
Oct-16-23 08:00AM	I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 (PR Newswire)
Oct-10-23 08:00AM	I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 (PR Newswire) +6.38%
Oct-05-23 05:17PM	Ray Dalio on Potential US-China War and Rise of China (Insider Monkey) +6.11% +5.04%
Sep-22-23 05:03PM	UPDATE 1-AbbVie terminates deal with I-Mab to develop cancer drug (Reuters) +6.67%
Sep-05-23 08:00AM	I-Mab Announces Upcoming Participation at September Conferences (PR Newswire) -7.73%

NovaBridge Biosciences operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.

Executive ChairmanMr. Wei Fu

Chief Financial OfficerMr. Ming Lei

Ph.D.Mr. Sean Wuxiong Cao M.B.A.

Ph.D.Dr. Xi-Yong Fu M.B.A.

President & Chief Commercial OfficerMr. Mark Hagler

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Xu Cong Claire	SVP, Clinical Development	Jul 06 '26	Sale	0.89	4,485	3,992	298,101	Jul 07 07:50 PM
Dennis Phillip Andrew	Chief Medical Officer	Jun 18 '26	Sale	0.66	8,494	5,606	157,941	Jun 22 05:23 PM
Xu Cong Claire	SVP, Clinical Development	Jun 01 '26	Sale	3.94	3,494	13,766	290,154	Jun 02 06:46 PM
Cao Sean Wuxiong	See Remarks	May 14 '26	Sale	1.99	21,399	42,584	35,073	May 18 04:05 PM
Cao Sean Wuxiong	Officer	May 14 '26	Proposed Sale	1.99	9,304	18,534		May 14 02:50 PM
Hagler Mark Arnold	See Remarks	Apr 24 '26	Buy	2.51	230,000	577,300	230,000	Apr 28 04:05 PM
Dennis Phillip Andrew	Chief Medical Officer	Mar 18 '26	Proposed Sale	2.79	3,638	10,153		Mar 18 04:08 PM
Skelton Joseph W.	Officer	Jan 02 '26	Proposed Sale	4.33	120,000	519,600		Jan 02 04:00 PM
Dennis Phillip Andrew	CHIEF MEDICAL OFFICER	Dec 18 '25	Proposed Sale	4.23	3,431	14,501		Dec 18 11:30 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NovaBridge Biosciences ADR

Upgrade your Finviz experience